Larimar Therapeutics’ stock plunges on FDA decision; will implement cost-cutting measures

The Food and Drug Administration dealt Larimar Therapeutics a setback when the agency decided to maintain its clinical hold on the Bala Cynwyd biotechnology company’s effort to develop a treatment for a rare condition

Leave a Reply